These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31940970)

  • 21. Taming molecular flexibility to tackle rare diseases.
    Cubellis MV; Baaden M; Andreotti G
    Biochimie; 2015 Jun; 113():54-8. PubMed ID: 25841341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological chaperone therapy for Fabry disease.
    Ishii S
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease.
    Lukas J; Knospe AM; Seemann S; Citro V; Cubellis MV; Rolfs A
    J Vis Exp; 2017 Dec; (130):. PubMed ID: 29286471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro expression study of four Fabry disease causing mutations at glutamine 279 of the alpha-galactosidase A protein.
    Dominissini S; Cariati R; Nevyjel M; Guerci V; Ciana G; Bembi B; Pittis MG
    Hum Hered; 2004; 57(3):138-41. PubMed ID: 15297807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.
    Okumiya T; Ishii S; Takenaka T; Kase R; Kamei S; Sakuraba H; Suzuki Y
    Biochem Biophys Res Commun; 1995 Sep; 214(3):1219-24. PubMed ID: 7575533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations.
    Shabbeer J; Yasuda M; Benson SD; Desnick RJ
    Hum Genomics; 2006 Mar; 2(5):297-309. PubMed ID: 16595074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.
    Matsuzawa F; Aikawa S; Doi H; Okumiya T; Sakuraba H
    Hum Genet; 2005 Aug; 117(4):317-28. PubMed ID: 15924232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry.
    Moise A; Maeser S; Rawer S; Eggers F; Murphy M; Bornheim J; Przybylski M
    J Am Soc Mass Spectrom; 2016 Jun; 27(6):1071-8. PubMed ID: 27112153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.
    Cimmaruta C; Citro V; Andreotti G; Liguori L; Cubellis MV; Hay Mele B
    BMC Bioinformatics; 2018 Nov; 19(Suppl 15):433. PubMed ID: 30497360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
    Yam GH; Roth J; Zuber C
    Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
    Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
    Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
    Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
    Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.